Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bridging pharma gmbh - pancreatis pulvis, aspergilli oryzae enzymata - confetti - pancreatis pulvis corresp. lipasum 7400 u. ph. eur. et proteasum 420 u. ph. eur. et amylasum 7000 u. ph. eur., aspergilli oryzae enzymata corresp. proteasum 10 u. fip et amylasum 170 u. fip et cellulasum (1974) 70 u. fip, saccharum 107.2 mg, talcum, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 11.7 mg, acidi methacrylici et ethylis acrylatis polymerisati 1:1 dispersio 30 per centum, polyacrylatis dispersio 30 per centum, calcii carbonas, povidonum k 25, titanii dioxidum, glycerolum (85 per centum), acaciae gummi, silica colloidalis anhydrica, triethylis citras, magnesii stearas, macrogolum 8000, simeticonum, macrogolum 35'000, glucosum liquidum 0.6 mg, hypromellosum, calcii lactas pentahydricus, cera carnauba, e 200 pro compresso obducto. - digestivum - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bridging pharma gmbh - heparinoidum (chondroitini polysulfas) - creme - heparinoidum (chondroitini polysulfas) 3 mg, corresp. 250 u., glycerolum (85 per centum), acidum stearicum, alcoholes adipis lanae, alcohol cetylicus et stearylicus 31.375 mg, vaselinum album, alcohol myristylicus, alcohol isopropylicus, kalii hydroxidum, e 218 1.6 mg, thymolum, propylis parahydroxybenzoas 0.4 mg, aqua purificata, ad unguentum pro 1 g. - venenmittel per l'uso esterno - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bridging pharma gmbh - heparinoidum (chondroitini polysulfas) - gel - heparinoidum (chondroitini polysulfas) 3 mg, corresp. 250 u., alcohol isopropylicus, acidum polyacrylicum, propylenglycolum 5 mg, natrii hydroxidum, aqua purificata, ad gelatum pro 1 g. - venenmittel per l'uso esterno - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - phenprocoumonum - compresse - phenprocoumonum 3 mg, lactosum 80 mg, maydis amylum, talcum, magnesii stearas pro compresso. - anticoagulans - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bridging pharma gmbh - bromocriptinum - compresse - bromocriptinum 2.5 mg ordine bromocriptini mesilas, silice colloidalis anhydrica, dinatrii edetas corrisp. sodio 0,06 mg, magnesio stearas, acido maleicum, maydis per amylum, per amylum pregelificatum, lactosum monohydricum 116 mg, pro compresso. - iperprolattinemia, prolaktinom, acromegalia, medico indicizzati laktationshemmung - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant adenovirus type 26 (ad26) encoding the glycoprotein (gp) of the ebola virus zaire (zebov) mayinga strain - febbre emorragica di ebola - vaccini - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Unione Europea - italiano - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant modified vaccinia ankara bavarian nordic virus encoding the: ebola virus zaire (zebov) mayinga strain glycoprotein (gp); ebola virus sudan gulu strain gp; ebola virus taï forest strain nucleoprotein and the marburg virus musoke strain gp - febbre emorragica di ebola - vaccini - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Unione Europea - italiano - EMA (European Medicines Agency)

viiv healthcare b.v. - cabotegavir sodium, cabotegravir - infezioni da hiv - antivirali per uso sistemico - vocabria tablets are indicated in combination with rilpivirine tablets for the short-term treatment of human immunodeficiency virus type 1 (hiv-1) infection in adults who are virologically suppressed (hiv-1 rna.

Unione Europea - italiano - EMA (European Medicines Agency)

janssen-cilag international nv - rilpivirine - infezioni da hiv - antivirali per uso sistemico - rekambys is indicated, in combination with cabotegravir injection, for the treatment of human immunodeficiency virus type 1 (hiv 1) infection in adults who are virologically suppressed (hiv-1 rna < 50 copies/ml) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the nnrti and ini class.

Italia - italiano - Ministero della Salute

smith & nephew orthopaedics ltd - componenti acetabolari per protesi di rivestimento